StockData

Vyome vs Incannex Healthcare

HIND and IXHL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How HIND and IXHL compare

Incannex Healthcare is the larger company, worth 2.0 times as much as Vyome ($21.8M against $10.8M).

Incannex Healthcare scores higher on the StockData Score (7 against 1 for Vyome), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricHINDIXHL
Size and price
Market cap$10.8M$21.8M
Share price$1.54$1.74
Change, 1 year−68.3%−83.5%
Change, 5 years−100.0%–
Beta (5Y)1.602.40
Employees1812
StockData Score
Total score17 (better)
Valuation score01 (better)
Growth score00
Performance score01 (better)
Health score15 (better)
Dividend score00
Valuation
P/S83.6×–
P/B–0.3×
FCF yield–−14.6%
Growth
Revenue growth (TTM)−67.1%–
Revenue growth, 5Y average−51.0%–
Profitability
Gross margin52.7%–
Operating margin−9190%–
Net margin−8717%–
Return on equity−194%−20.7% (better)
Return on invested capital−173% (better)−1945%
Financial health
Debt / equity–0.00
Interest coverage−285.8×–
Current ratio4.3767.79 (better)
Altman Z-score−13.57−0.22 (better)
Piotroski F-score44
Dividends and buybacks
Buyback yield39.6% (better)−42.2%
Shareholder yield39.6% (better)−42.2%
Ownership
Held by institutions2.0%3.6%
Held by insiders6.8%–
Short interest, % of float0.28%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.